New RSV vaccine for older adults can result in individual and societal cost savings, benefits
Vaccination against respiratory syncytial virus for adults over 60 is likely to be cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research.
Sep 5, 2024
0
0